Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer

(University of Texas M. D. Anderson Cancer Center) Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news